NCT01481194View on ClinicalTrials.gov

ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

August 28, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

Doxorubicin

50 mg/m2 IV on day 1 of a 21-day cycle

DRUG

Bortezomib

1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle

DRUG

Lenalidomide

15 mg orally on days 1-14 of a 21-day cycle

DRUG

Dexamethasone

20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle

DRUG

Cyclophosphamide

750 mg/m2 IV on day 1 of a 21-day cycle

Trial Locations (1)

Unknown

Department of Hematology, Vejle

All Listed Sponsors
collaborator

The University of Hong Kong

OTHER

lead

Vejle Hospital

OTHER

NCT01481194 - ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter